Tumor Imaging Metrics

The mission of the Tumor Imaging Metrics Core (TIMC) is to provide standardized, consistent, longitudinal radiological measurements to evaluate therapeutic response for DF/HCC clinical trials.


The TIMC -

  • Makes reliable, quantitative, longitudinal measurements (such as RECIST, WHO, SWOG, standardized uptake value [SUV] etc.) of lesions from serial MRI, CT, PET, and PET/CT scan images
  • Presents results of analyses on a password protected secure web-based report
  • Provides an independent service, with verifiable measurement of treatment response for patients enrolled in cancer center trials
  • Serves as a centralized, computerized resource to facilitate efficient internal or external auditing

Reliable tracking of changes in lesion size or metabolism is essential for clinical trials that use radiological measurements as surrogate endpoints. The Tumor Metrics Core provides a service for managing these images, making measurements in a routine, reliable, and centralized way, and making results available to investigators efficiently.

Group Members

Core Co-Director: Gordon Harris, PhD (MGH)
Core Co-Director: Annick Van den Abbeele, MD (DFCI)

Core Manager
Bill Hanlon
Telephone: 617-632-6578
Email: whanlon@partners.org

Lead Image Analyst
Trinity Urban
Telephone: 617-643-0296
Email: turban@partners.org

Image Analysis Specialist
Rob Zondervan
Telephone: 617-462-0327
Email: rzondervan@partners.org

Research Fellows
Marta Braschi, MD
Telephone: 617-643-0106
Email: mbraschi@partners.org

Gisele Cruz, MD
Telephone: 617-643-0106
Email: gpcruz@partners.org

Xiaozhou MA, MD
Telephone: 617-643-0299
Email: xma@partners.org

Facilities & Equipment

Core Location

Massachusetts General Hospital, 3D Imaging Service


The Tumor Metrics Core provides four primary services to DF/HCC investigators:

  • Consultation services for image-based protocol and image analysis design
  • Image aggregation and management of scans from all DF/HCC institutions
  • Image measurement of lesions from scans of patients on clinical trials
  • Reporting and database management of radiological data for clinical trials

The Tumor Imaging Metrics Core will maintain a database of longitudinal radiological and clinical data that will link to the Quality Assurance for Clinical Trials (QACT) Core to provide an auditable record of quantitative measurements for clinical trials conducted through the DF/HCC.

Fee Schedule

Included in the TIMC user fees are the following services; consultation with Trial PIs prior to trial initiation, image study capture from DF/HCC centers, image study archival for the length of the trial, tumor measurements as specified in the protocol, database management of measurement results and image snapshots, web-based results reporting and assistance with trial audits with respect to the image analysis components of the trial.

The TIMC offers consultative services to clinical trials investigators at no additional cost to DF/HCC investigators. The goal of the consultative service is to optimize clinical trials’ protocol design for imaging acquisition and analysis methods so that trials are established with appropriate and optimal imaging methods.

TIMC service fees (per scan) -- New rates apply to 09-xxx trials, effective 13-June-2008

Assessment Criteria DF/HCC member Non-DF/HCC member Industry sponsored
RECIST ch/ab/pel (CT/MR) $100 $200 $300
WHO, IWRC, neuro, ch/ab/pel (CT/MR) $200 $300
Cheson (NHL) neck/ch/ab/pel (CT/MR) $125 $250 $375
SUV neuro, maximum of five lesions (PET) $125 $250 $375
SUV whole body, maximum of five lesions (PET) $125 $250 $375
Choi 6 (CT w/contrast) $150 $300 $450
NCI-96 (CT/MR) $150 $300 $450
3D Volume – neuro, maximum of five lesions (MR) $150 $300 $450

RECIST – Response Evaluation Criteria for Solid Tumors (linear).

WHO – World Health Organization criteria (bi-directional).

IWRC – International Workshop Response Criteria (bi-directional).

Cheson – (sum of products of perpendicular diameters). An additional charge of one scan time-point will be applied if measurements must be repeated from baseline; i.e. if new target lesions are identified for a subject in accordance with Cheson response criteria guidelines.

SUV – Standard Uptake Value, using body weight formula

Choi – RECIST plus density measurements on CT scans w/contrast

3D Volume - Includes modified RECIST measurements for brain.

Getting Started


Core Manager
Bill Hanlon
Telephone: 617-632-6578
Email: whanlon@partners.org

Back to Top